| Outcome Measures: |
Primary: To assess the effect of repeated administrations of NBI-6024 on endogenous insulin production as measured by C-peptide levels in adult and adolescent patients with new onset type 1 diabetes mellitus, monthly assessments, up to 24 months (end of study) | Secondary: To examine the effects of repeated administrations of NBI-6024 on insulin usage, glycemic control, and immune function (immunodynamics and pharmacodynamics) To examine the safety and tolerability of repeated administrations of NBI-6024, monthly assessments, up to 24 months (end of study)
|
| Locations: |
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Center Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre de recherche clinique de Laval, Laval, Canada|University Hospital and School of Medicine, Olomouc, Czech Republic|Faculty Hospital Motol, Prague, Czech Republic|Helsinki University Hospital, Helsinki, Finland|Hôpital Debrousse, Lyons, France|Hôpital St Vincent de Paul, Paris, France|Diabetes Center for Children and Adolescents, Hannover, Germany|Institut für Diabetesforschung, Munchen, Germany|New Groote Schuur Hospital, Cape Town, South Africa|Parklands Medical Center, Durban, South Africa|Center for Diabetes and Endocrinology, Johannesburg, South Africa|Donald Gordon Medical Center, Johannesburg, South Africa|Medigate Medical Center, KwaZulu Natal, South Africa|Helderberg Diabetic Clinic and Practice, Somerset West, South Africa|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital de Cruces, Cruces-Baracado, Spain|Hospital Materno-Infantil, Malaga, Spain|University Hospital Virgen del Rocío, Sevilla, Spain|Maternal and Child Health Services 2, Dundee, United Kingdom
|